Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
| Descriptor ID |
D000964
|
| MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 4 | 0 | 4 |
| 2001 | 4 | 1 | 5 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 6 | 0 | 6 |
| 2006 | 4 | 0 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 5 | 1 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 7 | 1 | 8 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 4 | 0 | 4 |
| 2025 | 4 | 0 | 4 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
-
High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Glob Oncol. 2025 03; 11:e2400591.
-
Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Glob Oncol. 2025 03; 11:e2400450.
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 10; 71(10):e31213.
-
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 09; 71(9):e31169.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
-
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage. Pediatr Blood Cancer. 2020 09; 67(9):e28334.
-
Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 04; 67(4):e28123.